

NORTHWESTERN

UNIVERSITY

Transport of Drug and Virus in the Intravaginal Ring Treated Pigtail Macaque FRT Adina Ott¹, Katarina Kotnik Halavaty², Jonathan Su¹, Danijela Maric², Samuel Sung¹, Mark Marzinke³, Thomas Hope², Patrick Kiser¹ ¹Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208. ²Cell and Molecular Biology Department, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, ³Johns Hopkins University Department of Medicine, Clinical Pharmacology Analytical Laboratory (CPAL), 600 N. Wolfe St., Osler 523, Baltimore, MD 21287

BACKGROUND

Prevention of HIV transmission using a tenofovir disoproxil fumarate (TDF)-eluting in-Three pigtail macaques were treated with TDF-IVRs for 28 days, and vaginally challenged with a high dose of a replicative SIV mac 239 virus and a single round non-reptravaginal ring (IVR) requires the right drug at the right place at the right time. For the first time, we demonstrate the ability to locate the initial site of infection and measure the licative SIV-based vector expressing Luciferase and mCherry reporter genes (JRFL drug distribution within an IVR-protected macaque FRT. This work demonstrates that pseudotyped LICh vector). The isolated FRT was treated with luciferin to detect Lucifernot only is virus capable of infecting the ovaries, but that an IVR is also sometimes caase activity using IVIS, allowing us to identify the initial site of the infection. The tissue pable of achieving low drug concentrations there as well, highlighting the complexity of was sectioned and imaged further under IVIS. Tissue samples were processed and TFV transport within the FRT and the need for further experiments and modeling. and TFV-DP concentrations were quantified using LC-MS/MS, with ¹³C-labeled TFV as an internal standard.




Figure 2. Structures of Tenofovir Disoproxil Fumarate, the prodrug of tenofovir; monoPOC-TFV, Figure 5. Tissue processing protocol for quantification of TFV and TFV-DP. the intermediate metabolite of TDF; and tenofovir. TDF enters the cell and is hydrolyzed twice to form TFV.





Figure 3. Protection against HIV with tenofovir is accomplished when TFV is converted to tenofovir diphosphate inside cells. TFV-DP competes with its natural nucleotide complement deoxyadenosine 5'-triphosphate for incorporation into a growing HIV DNA chain. Upon incorporation, the HIV DNA chain elongation terminates.

METHODS







Figure 4. A. In vivo imaging systems (IVIS) of rhesus macaque reproductive tract 48 hours after inoculation with JRFL pseudotyped LICh vector. The reproductive tract is separated into large sections (panel 1; V1: labia and lower vagina; V2: upper vagina; C: cervix; U: uterus; O: ovary), soaked in d-luciferin to identify luciferase expressing regions with IVIS, and dissected into sequentially smaller pieces (panels 2–4) to isolate strongly luminescent regions measuring $2 \times 2 \text{ mm}^2$. **B**. Parts of the macaque female reproductive tract (FRT).








Figure 6. Quantification of TFV is accomplished by monitoring the m/Z 288 \rightarrow 176 fragment with HPLC-MS/MS in positive ion mode. The LLOQ for TFV is 63 fmol/mg tissue.





RESULTS







Infection events were detected in both ovaries in two animals and in one ovary of the third macaque using IVIS. TFV levels were found to be variable throughout the FRT, with the highest concentrations found in the upper vagina/lower cervical area, near the site of the ring. The concentration of TFV in the FRT of the macaques was in the range of 40-28,000 fmol/mg of tissue and the concentration of TFV-DP in the FRT of the macaques was in the range of 3-6000 fmol/mg of tissue. In the uterus and ovaries, the TFV concentration is at or near the IC_{50} of TFV in PBMC's.
















REFERENCES

1. Smith JM, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. PNAS, 2013, 110(40): 16145 - 16150. 2. Anderson PL, et al. *Pharmacological considerations for tenofovir and emtricitabine to prevent* HIV infection, J Antimicrob Chemother, 2011, 66: 240-250. 3. De Clercq E and Holy A, Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Reviews Drug Discovery, 2005, 4: 928-940. 4. Stieh DJ, et al. Vaginal Challenge with an SIV-Based Dual Reporter System Reveals That Infection Can Occur throughout the Upper and Lower Female Reproductive Tract. PLoS One, 2014, DOI: 10.1371/journal.ppat.1004440.




Figure 8. Average TFV levels in the FRTs of TDF-IVR treated pigtail macaques.

CONCLUSIONS

• Utilizing reporter viruses allows us to perform complete pharmacokinetic and pharmacodynamic studies at both the anatomical and cellular levels.

• Our results demonstrate the gradient of tissue drug levels emanating from the site of the ring. We observe lower drug levels in the upper reproductive tract for all animals.

• Infection events were seen in the ovaries of all three macaques, possibly reflecting the variability of ovarian drug levels (range of 7-30 fmol TFV-DP/mg of tissue) and virus transport.

ACKNOWLEDGEMENTS

This work was supported by the National Institutes of Health Grant U19 AI103461 and Northwestern University.

FURTHER INFORMATION

For further information, contact Professor Patrick Kiser: patrick.kiser@northwestern.edu